EUVIMEDEUVIMED entdecken
Fallbericht

Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors

Masaki Kumondai, Masafumi Kikuchi, Atsushi Mizuguchi, Nagomi Hayashi, Masahiro Ui, Takashi Hirama, Yoshinori Okada, Yu Sato, Toshihiro Sato, Masamitsu Maekawa, Nariyasu Mano

The Tohoku Journal of Experimental Medicine · 2023

DOI: 10.1620/tjem.2023.j016 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Tohoku Journal of Experimental Medicine, 2023. Verfasst von Masaki Kumondai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Tohoku University Hospital. Hauptthemen laut MEDLINE: Tacrolimus, Lymphangioleiomyomatosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with lymphangioleiomyomatosis (LAM) and lung transplantations are treated with multiple drugs, such as tacrolimus, mycophenolate mofetil, prednisolone, and itraconazole, for long-term suppression of rejection response and prevention of infection. Additional drugs are required when lung transplant recipients develop graft complications. Therefore, managing polypharmacy is critical because of drug-drug interactions caused by various factors, including drug-metabolizing enzymes such as cytochrome P450 3A (CYP3A). The patient was a 48-year-old woman (height 144.9 cm and weight 38.4 kg) who underwent lung transplantation for LAM. Mycophenolate mofetil, tacrolimus (target blood concentration, 4.0-8.0 ng/mL), and prednisolone were administered for immunosuppression, and itraconazole and clarithromycin were administered to manage graft infection. The patient developed unilateral lymphedema, predominantly in the left leg; therefore, sirolimus was initiated with a target blood concentration of 3.0-5.0 ng/mL. In addition to 1.0 mg/day of sirolimus, tacrolimus (0.3 mg/day), itraconazole (100 mg/day), and clarithromycin (800 mg/day) were added. Blood sirolimus concentrations ranged from 18.8 to 36.9 ng/mL on days 6 to 9; thus, treatment with sirolimus was stopped because of over-target blood concentrations. Blood concentrations of sirolimus and tacrolimus were successfully managed without adverse events using therapeutic drug monitoring (TDM) and azole anti-fungal substitution of azithromycin instead of clarithromycin although sirolimus concentration was relatively lower compared to the target range. Thereby, frequent TDM, management of polypharmacy that influences CYP3A activity, and possibly CYP3A genotyping should be appropriately conducted for personalized medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusLymphangioleiomyomatosisFemaleHumansMiddle AgedSirolimusImmunosuppressive AgentsCytochrome P-450 CYP3AMycophenolic AcidPolypharmacyItraconazoleDrug MonitoringClarithromycinPrednisolone

Stichwörter der Autor:innen

cytochrome P450 3Adrug–drug interactionslung transplantationlymphangioleiomyomatosistherapeutic drug monitoring

Substanzen

TacrolimusSirolimusImmunosuppressive AgentsCytochrome P-450 CYP3AMycophenolic AcidItraconazoleClarithromycinPrednisolone

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Tohoku University Hospital.
  • Faculty of Pharmaceutical Sciences, Tohoku University.
  • Department of Thoracic Surgery, Tohoku University Hospital.

Zitieren

APA

Kumondai, M., Kikuchi, M., Mizuguchi, A., Hayashi, N., Ui, M., Hirama, T., Okada, Y., Sato, Y., Sato, T., Maekawa, M., & Mano, N. (2023). Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors. The Tohoku Journal of Experimental Medicine. https://doi.org/10.1620/tjem.2023.j016

Vancouver

Kumondai M, Kikuchi M, Mizuguchi A, Hayashi N, Ui M, Hirama T, et al. Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors. The Tohoku Journal of Experimental Medicine. 2023. doi:10.1620/tjem.2023.j016

BibTeX
@article{Kumondai2023,
  author = {Kumondai, Masaki and Kikuchi, Masafumi and Mizuguchi, Atsushi and Hayashi, Nagomi and Ui, Masahiro and Hirama, Takashi and Okada, Yoshinori and Sato, Yu and Sato, Toshihiro and Maekawa, Masamitsu and Mano, Nariyasu},
  title = {Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors},
  journal = {The Tohoku Journal of Experimental Medicine},
  year = {2023},
  doi = {10.1620/tjem.2023.j016}
}
Kostenlos starten →